Cargando…
ATM protein is deficient in over 40% of lung adenocarcinomas
Lung cancer is the leading cause of cancer-related mortality in the USA and worldwide, and of the estimated 1.2 million new cases of lung cancer diagnosed every year, over 30% are lung adenocarcinomas. The backbone of 1(st)-line systemic therapy in the metastatic setting, in the absence of an action...
Autores principales: | Villaruz, Liza C., Jones, Helen, Dacic, Sanja, Abberbock, Shira, Kurland, Brenda F., Stabile, Laura P., Siegfried, Jill M., Conrads, Thomas P., Smith, Neil R., O'Connor, Mark J., Pierce, Andrew J., Bakkenist, Christopher J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5295384/ https://www.ncbi.nlm.nih.gov/pubmed/27259260 http://dx.doi.org/10.18632/oncotarget.9757 |
Ejemplares similares
-
ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
por: Dacic, Sanja, et al.
Publicado: (2016) -
Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation
por: Vendetti, Frank P., et al.
Publicado: (2017) -
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo
por: Vendetti, Frank P., et al.
Publicado: (2015) -
Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma: ATM, ATR and FA in lung carcinoma
por: Beumer, Jan H., et al.
Publicado: (2015) -
Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer
por: Siegfried, Jill M., et al.
Publicado: (2017)